A systematic review published in the Journal of Perinatology examines how antidepressant medication influences breastfeeding initiation, duration, and exclusivity, emphasising individualised approaches amid ongoing scientific uncertainties.
A new systematic review is sharpening attention on a difficult issue in perinatal care: whether antidepressant use during pregnancy or after birth is linked to changes in breastfeeding behaviour. Published in the Journal of Perinatology, the review by Desaunay, Blouet, Alexandre and colleagues looks beyond the simple question of whether mothers breastfeed at all. It examines initiation, duration, exclusivity and the reasons feeding patterns may shift in the fragile months after delivery.
The topic matters because depression and anxiety are common in pregnancy and the postnatal period, while breastfeeding remains widely encouraged for its health benefits. That can leave parents weighing two legitimate concerns at once: effective mental health treatment and the practical, emotional and medical realities of feeding a newborn. The review notes that breastfeeding decisions are shaped by many overlapping factors, including exhaustion, pain, birth complications, support at home, finances and the severity of the illness itself.
Earlier work has already shown how complex this area is. A review published in 2010 in Breastfeeding Medicine examined the safety of antidepressants in nursing mothers and set out pharmacokinetic data such as milk transfer, half-life and bioavailability. More recent reviews have suggested that some medicines, including sertraline and paroxetine, appear to have more favourable safety profiles than other serotonin-based antidepressants, although data on longer-term infant outcomes remain limited. Another literature review, published last year, said there is still too little known about how much antidepressant exposure reaches breast milk and what that means for babies.
That uncertainty is part of a broader scientific problem: people taking antidepressants are often not comparable with those who are not. As the new review emphasises, observational studies can be affected by confounding, meaning that depression, anxiety, socioeconomic pressures, smoking, birth complications and access to lactation support may all influence breastfeeding independently of medication use. The timing of exposure also matters. Antidepressant treatment during pregnancy may signal a pre-existing mental health condition, while treatment after delivery may reflect postpartum symptoms that arise just as lactation is being established.
A separate systematic meta-review on managing major depressive disorder in pregnant and breastfeeding women has recommended psychotherapy first for mild to moderate illness, with medication, especially selective serotonin reuptake inhibitors such as sertraline, as a second-line option. At the same time, a 2026 systematic review and meta-analysis on postpartum depression treatments found that about 40% of behavioural interventions improved breastfeeding exclusivity or duration, underscoring that the relationship between mental health care and feeding outcomes is not limited to drugs. Taken together, the literature suggests a field still marked by gaps, mixed methods and inconsistent definitions.
For families and clinicians, the practical message is unlikely to be a simple yes-or-no answer. The emerging evidence points instead to individualised decision-making that balances symptom severity, prior treatment response, the specific drug involved, infant health and the parent’s feeding goals. Abruptly stopping medication without medical advice can create its own risks. What the review adds is a clearer reminder that breastfeeding behaviour sits at the intersection of biology, psychology and daily life, and that understanding antidepressant exposure requires looking at all three.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
